Seattle Genetics taps Takeda as partner for lead antibody-drug conjugate
16 December 2009
Ian Haydock
Seattle Genetics has entered into a deal with
Takeda and its oncology subsidiary, Millennium, for the global development and commercialisation of its lead product candidate, the antibody-drug conjugate brentuximab vedotin.
The agreement is worth $60 million upfront to the US firm, which also...
Please Login to read the full article.
16 December 2009
Ian Haydock
The agreement is worth $60 million upfront to the US firm, which also...
Please Login to read the full article.
RELATED CONTENT
NEWS
- EMA accepts Takeda/Millennium's Adcetris for review
- Nearly smooth sailing predicted at ODAC for Seattle Genetics' lymphoma drug
- Nycomed rumours fly as Takeda braces itself for a post-Actos world
- Seattle Genetics wins priority review for Hodgkin's/ALCL drug, but US FDA splits app
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
